TGX-221 is a potent, selective, and cell permeable inhibitor of PI3K p110β. Inhibition appears to occur at the ATP binding site based on the observed increase in IC50 from 5 to ~50 nM at ATP concentrations of 50 µM and 1 mM, respectively. TGX-221 inhibits PtdIns-(3,4)-P2 production in platelets with an IC50 of 50 nM. Selective inhibition of PI3K p110β results in defective platelet thrombus formation and defines PI3K as a target for antithrombotic therapy.
Cell Commun Signal. 2022 Jul 7;20(1):102.
Circular dorsal ruffles disturb the growth factor-induced PI3K-AKT pathway in hepatocellular carcinoma Hep3B cells
TGX-221 purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | BT-474 and HCT-116 cell lines |
Preparation method | For measurement of proliferation, cells were seeded in triplicate at 2×103 cells/well in 96-well culture plates and incubated overnight to allow cell attachment. The cells were incubated with the TGX221-loaded PHA nanoparticles, empty PHA nanoparticles, or free TGX221 for 24, 48, and 72 h. At designated time intervals, cells were quantified by a crystal violet staining-based colorimetric assay (Kueng et al. 1989). Briefly, cells were fixed by addition of 100 μl of 2.5% glutaraldehyde solution andincubated at room temperature for 30 min. Plates were washed three times by submersion in PBS solution. Plates were air-dried and stained by addition of 100 μl of 0.1% solution of crystal violet dissolved in deionized water and incubated for 20 min at room temperature, excess dye was removed by extensive washing with deionized water, and plates were air-dried prior to bound dye solubilization in 100 μ1 of 10% acetic acid. The optical density of dye extracts was measured directly in plates using a microplate reader (Bio-Rad Laboratories, Inc., UK) at 570 nm. |
Concentrations | 0.2, 2 and 20 μ M |
Incubation time | 24, 48, and 72 h |
Animal Experiment | |
---|---|
Animal models | prostate cancer LAPC-4, LNCaP, 22RV1 and C4-2 cellsxenograft tumor in nude mice |
Formulation | dissolved in polypropylene glycol (PPG) |
Dosages | 100 mg/kg twice a week for 3 weeks |
Administration | tail vein injection |
Molecular Weight | 364.4 |
Formula | C21H24N4O2 |
CAS Number | 663619-89-4 |
Solubility (25°C) | DMSO 18 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related PI3K Products |
---|
SNV4818
SNV4818 is a potential best-in-class (best-in-class) mutation-selective PI3K-α inhibitor with excellent selectivity for the H1047X mutant and moderate selectivity for the related E545/542X mutant. |
hSMG-1 inhibitor 11j
hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. |
RLY-2608
RLY-2608 is a first-in-class, orally active, selective inhibitor of PI3Ka metabolism. |
EDI048
EDI048 is an orally active Cryptosporidium PI4K inhibitor for the research of cryptosporidiosis. |
PI3Kδ-IN-13
PI3Kδ-IN-13 is a PI3Kδ inhibitor (IC50=2.6 nM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.